[{"text": "Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice", "labels": [], "entities": []}, {"text": "Objectives: This study evaluated the effectiveness of behavioral interventions (brief counseling, nonspecific psychological support in groups \u0097 NSGS and cognitive behavioral group therapy \u0097 CBGT) in combination with bupropion SR for smoking cessation in the field, through a smoking cessation clinic.", "labels": [], "entities": []}, {"text": "Methods: Two-hundred-and-five smokers were enrolled in a 19 - week course during 2007/ 2008, and were randomly assigned to: bupropion SR combined with brief counseling (group A), bupropion SR combined with NSGS (group B), bupropion SR combined with CBGT (group C), or CBGT as the only approach (group D).", "labels": [], "entities": []}, {"text": "Results: Continuous abstinence rates at the end of therapy were 53.2% for group A, 62.9% for group B, 50.0% for group C, and 22.2% (p < 0.05) for group D.", "labels": [], "entities": [{"text": "22.2", "start_pos": 125, "end_pos": 129, "type": "Outcome_value", "confidence": 0.9221055507659912}]}, {"text": "Sustained abstinence rates in 12 months were 29.6%, 28.1%, 34.3% and 19.4% (p > 0.05), respectively.", "labels": [], "entities": [{"text": "29.6", "start_pos": 45, "end_pos": 49, "type": "Outcome_value", "confidence": 0.9592886567115784}, {"text": "28.1", "start_pos": 52, "end_pos": 56, "type": "Outcome_value", "confidence": 0.9588820338249207}, {"text": "34.3", "start_pos": 59, "end_pos": 63, "type": "Outcome_value", "confidence": 0.9251450300216675}, {"text": "19.4", "start_pos": 69, "end_pos": 73, "type": "Outcome_value", "confidence": 0.9441247582435608}]}, {"text": "Conclusions: Bupropion SR is an effective aid for smoking cessation in clinical practice.", "labels": [], "entities": []}, {"text": "NSGT increased the chances for success at the end of therapy when combined with bupropion SR, while CBGT as monotherapy was less effective compared with the approaches including pharmacotherapy.", "labels": [], "entities": []}, {"text": "It is suggested that smoking cessation interventions in real-life healthcare settings should be implemented through comprehensive programs using pharmacotherapy where applicable, combined with NSGT, and integrated by specialized healthcare professionals.", "labels": [], "entities": []}, {"text": "Several placebo-controlled studies of bupropion SR for smoking cessation have demonstrated it as effective in promoting smoking cessation, especially when combined with minimal counseling, as defined by the guidelines.", "labels": [], "entities": []}, {"text": "Furthermore, there is increasingly data supporting the effectiveness and cost-effectiveness of the implementation of other behavioral interventions combined with bupropion SR, nicotine replacement therapy (NRT), or combination of those two in actual practice, both in outpatient clinical settings and in hospitalized patients.", "labels": [], "entities": []}, {"text": "The term 'behavioral intervention' is used in abroad sense, to mean clinician-to-patient spoken therapy, which can range in intensity and sophistication from the single very brief session of advice to stop smoking to complex multisession formal cognitive \u0097 behavioral therapy.", "labels": [], "entities": []}, {"text": "In practice, clinicians tend to use an eclectic approach, selecting elements from all intensities of counseling, on the basis of the needs and constraints of the smoker they support.", "labels": [], "entities": []}, {"text": "However, although the contribution of behavioral therapy in increasing success rates of quitting smoking is established in clinical trials there is a well-recognized gap between research findings and the implementation of evidence-based smoking cessation strategies in community settings.", "labels": [], "entities": []}, {"text": "Therefore, the clinical utility and efficacy of these treatments in actual practice is still unclear, since there are several aspects limiting the effectiveness of smoking cessation efforts in real life.", "labels": [], "entities": []}, {"text": "The principal aim of this study was to evaluate the effectiveness, in terms of abstinence rates at the end of therapy and long-term abstinence (1 year), of the combination of bupropion SR and three different types of behavioral intervention (brief counseling, nonspecific psychological support in groups \u0097 NSGS and cognitive behavioral group therapy \u0097 CBGT) for smoking cessation in actual practice conditions and compare them with the implementation of CBGT alone.", "labels": [], "entities": []}, {"text": "A 19 - week smoking cessation program was integrated by professional clinicians, in a specialized outpatient smoking cessation clinic, in smokers self-referred to the department, willing to quit, and abstinence rates were recorded at the end of treatment and during 1 year of follow-up.", "labels": [], "entities": []}, {"text": "This was an open-label study that recruited smokers from the Smoking Cessation Clinic of 'Evgenidion.", "labels": [], "entities": []}, {"text": "A total of 405 Caucasian current smokers, were screened and 205 of those participated in the study [mean age x\u00b1SE, 44.9\u00b10.49] [].", "labels": [], "entities": [{"text": "405", "start_pos": 11, "end_pos": 14, "type": "Individual-level_analysed", "confidence": 0.6718093156814575}]}, {"text": "All participants were self-referred to the clinic and motivated to stop smoking.", "labels": [], "entities": []}, {"text": "All subjects who discontinued treatment or were lost during the follow-up period were classified as failures.", "labels": [], "entities": []}, {"text": "Subjects were eligible for inclusion if they were at least 18 years of age, had smoked an average of 15 cigarettes or more per day for the past year, were motivated to stop smoking, and did not have serious health problems.", "labels": [], "entities": [{"text": "15", "start_pos": 101, "end_pos": 103, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.8727887272834778}]}, {"text": "Exclusion criteria included the presence or a family history of a seizure disorder; a history of severe head trauma; predisposition to seizures (such as a history of brain tumor or stroke); a history or current diagnosis of anorexia nervosa or bulimia; the presence of an unstable medical or psychiatric condition; pregnancy; lactation; a history of dependence on alcohol or a nonnicotine substance within the past year; current use of psychotropic medications, fluoxetine, clonidine, buspirone or doxepin; previous use of bupropion; and current use of any nicotine replacement therapy.", "labels": [], "entities": []}, {"text": "Subjects with current depression, as assessed by the psychiatrist of the program, were also excluded.", "labels": [], "entities": []}, {"text": "The study was approved by the ethics committee of the hospital.", "labels": [], "entities": []}, {"text": "At baseline visit, each subject was receiving brief, personalized advice to stop smoking from the pulmonary physician of the clinic.", "labels": [], "entities": [{"text": "brief, personalized advice to stop smoking", "start_pos": 46, "end_pos": 88, "type": "4.5._Advise_to_change_behavior", "confidence": 0.6952716665608543}]}, {"text": "This first introduction aimed to provide information about the hazards of smoking in health, about nicotine dependence and strategies available for quitting smoking.", "labels": [], "entities": [{"text": "information about the hazards of smoking in health", "start_pos": 41, "end_pos": 91, "type": "5.1_Information_about_health_consequences", "confidence": 0.6818404458463192}]}, {"text": "Additionally, it aimed at introducing the study procedure to smokers in order to give their consent for enrolling.", "labels": [], "entities": []}, {"text": "Therapeutic Advances in Respiratory Disease 3 (6)", "labels": [], "entities": []}, {"text": "Participants completed: (a) demographic information about factors known to be important in influencing the uptake of smoking, such as smoking among family members, parental smoking, working environment and smoking policy in working place, and soon; (b) questionnaires regarding smoking attitudes and smoking dependence (Fagerstr\u00f6 m test for nicotine dependence); and (c) Beck Depression Inventory scale (BDI) for the evaluation of depression.", "labels": [], "entities": []}, {"text": "The FTND scores were classified as mild (0\u00973), moderate (4\u00977), and high addiction (8\u009710).", "labels": [], "entities": []}, {"text": "The BDI scores were classified as minimal (0\u009713), mild (14\u009719), moderate (20\u009728), and severe (29\u009763).", "labels": [], "entities": []}, {"text": "Medical history and physical examination were then assessed.", "labels": [], "entities": []}, {"text": "Target quit date (TQD) was set the second week of therapy with bupropion SR, usually on days 10\u009715, and the same timetable was followed in the CBGT group too.", "labels": [], "entities": []}, {"text": "Subjects were assessed with spirometry (MasterScreen, Jaeger, Hoechberg, Germany) and measurements of exhaled carbon monoxide (CO) and nitric oxide (NO) were recorded (LR 2000 Analyser, Rochester, UK).", "labels": [], "entities": [{"text": "exhaled carbon monoxide (CO)", "start_pos": 102, "end_pos": 130, "type": "Biochemical_verification", "confidence": 0.7124731043974558}]}, {"text": "Furthermore, there was a regular notification of body weight and blood pressure at each visit.", "labels": [], "entities": []}, {"text": "These measurements were recorded at each week of the first month of treatment, and every 3 weeks for the rest of the study period.", "labels": [], "entities": []}, {"text": "Spirometry test was repeated in 6 months and 1 year after smoking cessation.", "labels": [], "entities": []}, {"text": "Self-reported abstinence was considered validated by a carbon monoxide level in expired air of 10 ppm (parts per million) or below.", "labels": [], "entities": [{"text": "carbon monoxide level", "start_pos": 55, "end_pos": 76, "type": "Biochemical_verification", "confidence": 0.8655623197555542}, {"text": "expired air", "start_pos": 80, "end_pos": 91, "type": "Biochemical_verification", "confidence": 0.7774511575698853}]}, {"text": "Subjects were randomly assigned to attend one of the four following smoking cessation programs for 19 weeks:", "labels": [], "entities": []}, {"text": "Group A: bupropion SR and individual brief (15 minutes) counseling by the chest physician of the clinic.", "labels": [], "entities": [{"text": "Group A: bupropion SR and", "start_pos": 0, "end_pos": 25, "type": "Arm_name", "confidence": 0.6124399403731028}, {"text": "individual", "start_pos": 26, "end_pos": 36, "type": "Individual", "confidence": 0.9638495445251465}]}, {"text": "Group B: bupropion SR in combination with a nonspecific supportive and motivational group therapy (NSGT) conducted by a specialized psychologist.", "labels": [], "entities": []}, {"text": "Group C: bupropion SR in combination with a specific cognitive behavioral group therapy (CBGT) conducted by a specialized psychologist.", "labels": [], "entities": [{"text": "Group C: bupropion SR", "start_pos": 0, "end_pos": 21, "type": "Arm_name", "confidence": 0.7067573070526123}]}, {"text": "Group D: cognitive behavioral group therapy (CBGT) conducted by a specialized psychologist.", "labels": [], "entities": []}, {"text": "Bupropion SR was given at a dose of 150 mg per day for the first 6 days, 150 mg b.d. for 7 weeks and 150 mg once a day for the rest of the treatment period (19 weeks in total).", "labels": [], "entities": []}, {"text": "The prolonged treatment with bupropion SR was introduced in order to be inline with the schedule of the 19 week behavioral therapy, since there is no contraindication for the longer duration of treatment with the drug].", "labels": [], "entities": []}, {"text": "Behavioral therapy in groups rather than the individual sessions was chosen for reasons of efficacy, since it is thought that group members can exert peer pressure to motivate each other to maintain an effort to stop smoking.", "labels": [], "entities": []}, {"text": "Continuous abstinence from smoking at the end of therapy, as well as measurements of efficacy and safety throughout the treatment and follow-up phases were evaluated.", "labels": [], "entities": [{"text": "smoking", "start_pos": 27, "end_pos": 34, "type": "Smoking", "confidence": 0.779489278793335}]}, {"text": "Follow-up visits during treatment were set every week the first month of therapy and every 3 weeks thereafter, till the completion of treatment.", "labels": [], "entities": []}, {"text": "In group A, chest physicians' short advice included provision of information about the effects of smoking on health, information about nicotine dependence and tobacco withdrawal symptoms, strategies for quitting (e.g. making a quitting plan, managing stress and weight gain) and avoiding relapse.", "labels": [], "entities": [{"text": "information about the effects of smoking on health", "start_pos": 65, "end_pos": 115, "type": "5.1_Information_about_health_consequences", "confidence": 0.6692280694842339}]}, {"text": "Information was given about the correct use of medication and the expectations of its contribution in the smoking cessation effort.", "labels": [], "entities": []}, {"text": "Physicians were trying to build a relationship of trust and confidence with the smoker, so although the duration of each follow-up visit was initially set as 15 minutes in several occasions it could last up to an hour.", "labels": [], "entities": []}, {"text": "The sessions for the NSGT and the CBGT were set once a week for the first month and every 3 weeks thereafter for the 19 - week period of treatment, and were supported by specialized psychologists.", "labels": [], "entities": []}, {"text": "Every group consisted of at the most of 10 participants and the duration of the session was set as an hour.", "labels": [], "entities": []}, {"text": "In the group that received NSGT there was training of behavioral skills (based on learning theory), including learning and rehearsing new behaviors (e.g. refusing cigarettes), use response substitution, and monitoring and planning for N Rovina, I Nikoloutsou et al.", "labels": [], "entities": []}, {"text": "At each visit, concomitant medication use, adverse events and smoking abstinence were recorded.", "labels": [], "entities": [{"text": "smoking", "start_pos": 62, "end_pos": 69, "type": "Smoking", "confidence": 0.7403413653373718}]}, {"text": "Additionally, specific questionnaires were recorded regarding smoking attitudes, depressive mood (assessed by DSM IV symptom score) [American Psychiatric and withdrawal symptoms (Wisconsin scale).", "labels": [], "entities": []}, {"text": "Individual counseling (approximately 10\u009730 minutes) provided by the same physician at each visit in all groups.", "labels": [], "entities": [{"text": "Individual", "start_pos": 0, "end_pos": 10, "type": "Individual", "confidence": 0.9449673295021057}, {"text": "counseling", "start_pos": 11, "end_pos": 21, "type": "3.1_Social_support_(unspecified)", "confidence": 0.8031346201896667}]}, {"text": "Follow-up visits were scheduled at 3, 6, 9 and 12 months after the 19 - week period of treatment.", "labels": [], "entities": [{"text": "12", "start_pos": 47, "end_pos": 49, "type": "Longest_follow_up", "confidence": 0.9913873076438904}]}, {"text": "If a smoker missed a visit a telephone contact was made to reschedule the appointment.", "labels": [], "entities": [{"text": "telephone", "start_pos": 29, "end_pos": 38, "type": "Distance", "confidence": 0.8515980839729309}]}, {"text": "Smokers had the opportunity of a telephone contact with the doctors of the study in the case of aside effect or for asking for support.", "labels": [], "entities": []}, {"text": "Counseling during follow-up mainly focused on relapse prevention and on reinforcement of the effort remaining abstinent.", "labels": [], "entities": []}, {"text": "If smokers had quit smoking successfully advice was given about how to remain abstinent.", "labels": [], "entities": []}, {"text": "If smokers had a relapse in smoking during follow-up period anew effort was recommended.", "labels": [], "entities": []}, {"text": "Descriptive data are presented as mean\u00b1SEM.", "labels": [], "entities": []}, {"text": "The primary outcome variable was continuous abstinence rate at the end of therapy, at 6 and 12 months of follow-up.", "labels": [], "entities": [{"text": "12", "start_pos": 92, "end_pos": 94, "type": "Longest_follow_up", "confidence": 0.9934951663017273}]}, {"text": "Chi square test and analysis of variance were used to evaluate baseline differences in demographic and smoking history variables.", "labels": [], "entities": []}, {"text": "Chi square test was used to assess differences in abstinence rates between groups at the end of treatment, at 3, 6 and 12 months.", "labels": [], "entities": [{"text": "12", "start_pos": 119, "end_pos": 121, "type": "Longest_follow_up", "confidence": 0.9913634061813354}]}, {"text": "Two-tailed p values of <0.05 were considered significant.", "labels": [], "entities": [{"text": "0.05", "start_pos": 24, "end_pos": 28, "type": "Effect_size_p_value", "confidence": 0.7079662680625916}]}, {"text": "Logistic regression analysis was used to determine differences among groups in the abstinence rates and for the calculation of odds ratios (OR) and 95% confidence intervals (CIs).", "labels": [], "entities": [{"text": "odds ratios (", "start_pos": 127, "end_pos": 140, "type": "Odds_Ratio", "confidence": 0.8106765349706014}, {"text": "OR", "start_pos": 140, "end_pos": 142, "type": "Odds_Ratio", "confidence": 0.552903950214386}]}, {"text": "Smokers' baseline characteristics are shown in.", "labels": [], "entities": []}, {"text": "Group B was more dependent on nicotine, as assessed by FTND, but the difference between the groups was not statistically significant (p > 0.05).", "labels": [], "entities": [{"text": "Group B", "start_pos": 0, "end_pos": 7, "type": "Arm_name", "confidence": 0.9055249989032745}, {"text": "0.05", "start_pos": 138, "end_pos": 142, "type": "Effect_size_p_value", "confidence": 0.8823449611663818}]}, {"text": "Furthermore, smokers of group B had statistically significantly more failed previous attempts to quit compared with the smokers of the other groups (p < 0.05).", "labels": [], "entities": [{"text": "0.05", "start_pos": 153, "end_pos": 157, "type": "Effect_size_p_value", "confidence": 0.8822904825210571}]}, {"text": "All subjects had a mild to moderate depression score evaluated by Beck Depression Inventory.", "labels": [], "entities": []}, {"text": "From 405 patients screened, 162 just took information about the program without enrolling (low motivation, other preventive factors), 38 were excluded for medical reasons and 205 took part in the study.", "labels": [], "entities": [{"text": "162", "start_pos": 28, "end_pos": 31, "type": "Individual-level_analysed", "confidence": 0.6379415988922119}]}, {"text": "All of them completed treatment, while 184 (90%) completed the 12 - month follow-up.", "labels": [], "entities": [{"text": "184", "start_pos": 39, "end_pos": 42, "type": "Individual-level_analysed", "confidence": 0.6312229037284851}]}, {"text": "Of the total number of smokers 46% succeeded continuous abstinence at the end of therapy while 13% succeeded smoking reduction.", "labels": [], "entities": []}, {"text": "At the end of treatment (19 weeks) continuous abstinence rates were higher in the groups including combined therapy compared with the CBGT group (OR: 0.251, 95% CI: 0.104\u00970.609), with group B (bupropion SR in combination with NSGT) achieving higher abstinence rates compared with all the other groups, without exhibiting a statistically significant difference with the other combination groups (,).", "labels": [], "entities": []}, {"text": "After 6 months of follow-up continuous abstinence rates were similar in between the groups including bupropion SR (p < 0.05) (,), while group D still had statistically Therapeutic Advances in Respiratory Disease 3 (6) significantly lower abstinence rates compared with all the groups including bupropion SR (OR: 0.359, 95% CI: 0.147\u00970.875 and OR: 0.041, 95% CI: 0.161\u00970.961, respectively) (,).", "labels": [], "entities": []}, {"text": "Finally, after 1 year of follow-up continuous abstinence rates were still higher in the groups including bupropion SR compared to the CBGT group, but there was no statistically significant difference in between them (OR: 0.573, 95% CI: 0.221\u00971.487) (,).", "labels": [], "entities": [{"text": "OR", "start_pos": 217, "end_pos": 219, "type": "Odds_Ratio", "confidence": 0.9146274328231812}]}, {"text": "All smokers tolerated well bupropion SR, and mild adverse events were recorded.", "labels": [], "entities": []}, {"text": "The results of our study support the notion that the combination of behavioral interventions with bupropion SR is effective when implemented in multicomponent smoking cessation programs integrating support in actual clinical practice, and furthermore that it achieves higher longterm abstinence rates than those referred to behavioral therapy alone or no intervention at all.", "labels": [], "entities": []}, {"text": "All groups including bupropion SR showed high abstinence rates, with minor differences, statistically not significant, between them, with bupropion SR plus NSGT being more effective compared with bupropion SR combined either with brief counseling or with CBGT.", "labels": [], "entities": []}, {"text": "Abstinence rates achieved in group A (bupropion SR and brief counseling) were comparable to other studies using similar approach].", "labels": [], "entities": []}, {"text": "Furthermore, no differences were observed in abstinence rates in Groups A and C at the end of therapy, although smokers of group C received the special approach of the more sophisticated CBGT.", "labels": [], "entities": []}, {"text": "Although the number of participants in this group was low, this finding is in agreement with the results of both Cochrane and the USDHHS (United States  Department of Health and Human Services)] meta-analyses of studies assessing the effect of brief one-to-one and group counseling to stop smoking by generalist physicians over no intervention.", "labels": [], "entities": []}, {"text": "Both have shown that counseling raises the chances of successfully quitting by around 50% (OR: 1.69 and 1.3, respectively).", "labels": [], "entities": []}, {"text": "Undoubtedly, here the contribution of physicians' training and experience in the topic of smoking cessation should be considered.", "labels": [], "entities": []}, {"text": "Strong evidence indicates that physicians increase their patient's smoking cessation rates by providing smokers with advice and assistance to help them quit.", "labels": [], "entities": []}, {"text": "However, physicians in healthcare settings usually lack confidence in counseling skills, lack experience in the use of pharmacotherapy and more often lack the time to integrate a proper approach for smoking cessation advice and support.", "labels": [], "entities": []}, {"text": "In our specialized clinic for smoking cessation, health professionals involved in the program not only were adequately trained to integrate brief cessation advice, but they also had the ability to invest time and deal with smokers' problems, offering a more intensive counseling approach, which could merely explain the lack of difference in success rates between those two groups.", "labels": [], "entities": []}, {"text": "NSGT offered higher abstinence rates at the end of therapy when combined with bupropion SR compared with the other groups, although the smokers of this group were more dependent on nicotine, had more failed previous attempts, and higher smoking history than the other groups (higher mean exhaled CO, higher cigarette consumption and more smoking years).", "labels": [], "entities": []}, {"text": "This fact further supports the concept that intensive, nonspecific counseling integrated by specialized psychologists contributes at large to increasing the chances fora successful outcome.", "labels": [], "entities": []}, {"text": "The prolonged duration of bupropion SR treatment (19 weeks over the recommended 7 weeks) did not contribute to increasing quit rates, nor at the end of therapy or in 1 year of follow-up, since the results of another study conducted in our department in actual practice, which compared short (7 weeks) and prolonged (19 weeks) treatment with bupropion SR for smoking cessation, showed significant difference in abstinence rates in favour of short treatment at the end of therapy (72% versus 53%, p < 0.001).", "labels": [], "entities": [{"text": "0.001", "start_pos": 499, "end_pos": 504, "type": "Effect_size_p_value", "confidence": 0.9604159593582153}]}, {"text": "Furthermore, the cost of the prolonged treatment was almost three-fold higher compared to the short-term course.", "labels": [], "entities": []}, {"text": "A control group receiving bupropion SR for 7 weeks was not used since the effect of duration of treatment was not the objective of this study.", "labels": [], "entities": []}, {"text": "Our results indicate that without medication to alleviate tobacco withdrawal symptoms, the vast majority of more dependent smokers will fail to stop, even when they are highly motivated.", "labels": [], "entities": []}, {"text": "This is further supported by the results of group D, in which smokers that received just cognitive behavioral therapy showed lower abstinence rates at the end of therapy, and at all the timepoints of follow-up.", "labels": [], "entities": []}, {"text": "There is a controversy in opinions regarding the benefit behavioral counseling offers, which is mainly based in the significant heterogeneity among the behavioral interventions (e.g. intensity of intervention).", "labels": [], "entities": []}, {"text": "In practice, clinicians tend to use an eclectic approach, selecting elements from all intensities of counseling, on the basis of the needs and constraints of the smoker they support.", "labels": [], "entities": []}, {"text": "For those smokers willing to participate in programs using behavioral therapy, it has been shown that cessation rates average 20% after 1 year, in the range of 10\u009730%.", "labels": [], "entities": []}, {"text": "The results of group Dare inline with these data.", "labels": [], "entities": []}, {"text": "Our results are comparable or in some cases better than those seen in studies implementing the combination of nicotine replacement therapy (NRT) with behavioral therapy] in the clinical field.", "labels": [], "entities": []}, {"text": "Ina study assessing the clinical utility and efficacy in the clinical field of the NRT plus cognitive behavioral therapy, there was a 58.5% abstinence rate at the end of treatment, while in 5 years of follow-up sustained abstinence rate was 33.1%.", "labels": [], "entities": []}, {"text": "A placebo control group was not used in our study, since the effectiveness of bupropion SR and behavioral therapy was established previously in clinical trials and our study was initially designed as open in order to evaluate the effectiveness of these interventions in the real clinical field, under pragmatic conditions.", "labels": [], "entities": []}, {"text": "Therapeutic Advances in Respiratory Disease 3 (6)", "labels": [], "entities": []}, {"text": "Throughout the year of follow-up sustained abstinence rates were similar among the groups using bupropion SR.", "labels": [], "entities": []}, {"text": "Nowadays, there is enough evidence from a series of clinical trials that treatment with bupropion SR is effective in relapse prevention in smokers who have successfully quit.", "labels": [], "entities": []}, {"text": "Ina prospective study conducted in a primary care setting on military veterans of the US Army, who were allocated to treatment with bupropion SR, nicotine patch or combination therapy for 3 months with additional cognitive behavioral therapy, abstinence rates at 3 and 6 months were 32% and 28%, respectively, for bupropion SR; 43% and 34%, respectively, for combination treatment; and 19% and 15%, respectively, for nicotine patch.", "labels": [], "entities": []}, {"text": "The higher sustained abstinence rates observed in our study could be partly explained by the fact that all the participants were selfreferred to the clinic, as they were self-motivated to quit.", "labels": [], "entities": []}, {"text": "Furthermore, they were offered sustained motivation during the treatment phase and over the course of the 12 - month follow-up, with special support in the context of relapse-prevention (visits every three months, telephone contact with the nurse or the physician of the clinic whenever they needed help in an unscheduled basis).", "labels": [], "entities": []}, {"text": "However, despite sustained motivation during treatment phase and over the course of the 12 - month follow-up, relapse was not prevented in 1 year.", "labels": [], "entities": []}, {"text": "Relapse after initial successful abstinence remains a major treatment issue, despite the increasing array of effective pharmacotherapies that have been proved very helpful for smokers trying to quit . Smoking relapse within the first year after quitting is estimated at 60\u009790%.", "labels": [], "entities": []}, {"text": "The importance of intensity in behavioral programs has already been underlined in other studies.", "labels": [], "entities": []}, {"text": "Regular follow-up sessions designed according to recommended relapse prevention strategy played an important role in the successful outcome in our study, and indeed were accepted by smokers as helpful and supportive to their effort for remaining abstinent.", "labels": [], "entities": []}, {"text": "Interestingly, abstinence rates in the group receiving cognitive therapy were sustained throughout the year of follow-up.", "labels": [], "entities": []}, {"text": "Studies of relapse prevention strategies teaching coping skills have shown that they may reduce the risk of relapse, but other behavioral therapies have shown little benefit.", "labels": [], "entities": []}, {"text": "In our clinical experience, cognitive behavioral therapy was the least effective in achieving smoking cessation, and least popular among smokers as intervention, but smokers who eventually stopped smoking did not relapse in the preceding year.", "labels": [], "entities": []}, {"text": "This probably has to do with the type of intervention, which is aimed at teaching techniques that change thoughts, beliefs and attitudes to quitting and to manage negative mood.", "labels": [], "entities": []}, {"text": "However, in our study, the low number of participants does not allow the generalization of this observation.", "labels": [], "entities": []}, {"text": "Our results indicate that in clinical practice there is no need for the use of more sophisticated and eventually less cost-effective counseling approaches, as an addition to medical treatment for smoking cessation.", "labels": [], "entities": []}, {"text": "It is evident that the estimation of a dose\u0097response relationship between success rates and the number follow-up sessions, as well as the total contact time between smoker, specialized psychologist and clinician is demonstrated here.", "labels": [], "entities": []}, {"text": "Bupropion SR has been found very efficacious and well tolerated for treating individuals dependent on tobacco, and according to clinical guidelines for smoking cessation, unless medically contraindicated pharmacotherapy should be used in all assisted quitting attempts.", "labels": [], "entities": []}, {"text": "Prolonged duration of treatment with bupropion SR is not recommended as it was not shown to be costeffective compared with the short-term treatment.", "labels": [], "entities": []}, {"text": "One should not neglect the fact that pharmacotherapy and behavioral therapy have different but complementary roles in enhancing the chance of success in smoking cessation.", "labels": [], "entities": []}, {"text": "Therefore, healthcare professionals that have special responsibility and commitment to treating smokers should be well trained to undertake counseling on a routine basis and comfortable with the use and application of the several pharmacotherapies for smoking cessation in actual practice, while it is recommended specialized psychologists to be included in all the multicomponent smoking cessation clinics.", "labels": [], "entities": []}, {"text": "project, as well as A.", "labels": [], "entities": []}, {"text": "Alexandri, Dr Z. Athanassa and Z. Sarlani for their assistance in laboratory measurements and in patient motivation, in order to comply with the follow-up schedule.", "labels": [], "entities": []}, {"text": "All the authors of this paper declare that they have no financial or other potential conflicts of interest concerning the subject of this manuscript.", "labels": [], "entities": []}, {"text": "Molyneux, A., Lewis, S., Leivers, U., Anderton, A., Antoniak, M., Clinical trial comparing nicotine replacement therapy (NRT) plus brief counseling, brief counseling alone, and minimal intervention on smoking cessation in hospital inpatients.", "labels": [], "entities": []}, {"text": "Thorax 58: 484\u0097488.", "labels": [], "entities": []}, {"text": "The Previous use of nicotine patch (%) of Group A: n \u00bc 94: 30.5/69.5: 44.65\u00b11.25: 37.8\u00b11.7: 48.4\u00b13.6: 3.3\u00b10.4 has a value of 28.1.", "labels": [], "entities": []}, {"text": "The Previous use of nicotine patch (%) of Group B: n \u00bc 35: 34.3/65.7: 45.3\u00b11.5: 38.1\u00b12.38: 49.4\u00b14.8: 9.1\u00b13.6* has a value of 34.3.", "labels": [], "entities": []}, {"text": "The Previous use of nicotine patch (%): 35 of Group D: n \u00bc 36: 52.8/47.2: 44.5\u00b11.5: 34.2\u00b12.5: 44\u00b14.2: 4.9\u00b11.2 has a value of 33.3.", "labels": [], "entities": []}, {"text": "The Other smokers in the household (%) of Group A: n \u00bc 94: 30.5/69.5: 44.65\u00b11.25: 37.8\u00b11.7: 48.4\u00b13.6: 3.3\u00b10.4: 27.2\u00b12 has a value of 41.5.", "labels": [], "entities": []}, {"text": "The Other smokers in the household (%) of Group B: n \u00bc 35: 34.3/65.7: 45.3\u00b11.5: 38.1\u00b12.38: 49.4\u00b14.8: 9.1\u00b13.6*: 35.3\u00b12.8 has a value of 34.3.", "labels": [], "entities": []}, {"text": "The Other smokers in the household (%): 50 of Group D: n \u00bc 36: 52.8/47.2: 44.5\u00b11.5: 34.2\u00b12.5: 44\u00b14.2: 4.9\u00b11.2: 32.2\u00b13.2 has a value of 41.7.", "labels": [], "entities": []}, {"text": "The Level of education (%) of Group A: n \u00bc 94: 30.5/69.5: 44.65\u00b11.25: 37.8\u00b11.7: 48.4\u00b13.6: 3.3\u00b10.4: 27.2\u00b12 has a value of 4.9.", "labels": [], "entities": []}, {"text": "The Level of education (%) of Group B: n \u00bc 35: 34.3/65.7: 45.3\u00b11.5: 38.1\u00b12.38: 49.4\u00b14.8: 9.1\u00b13.6*: 35.3\u00b12.8 has a value of 2.9.", "labels": [], "entities": []}, {"text": "The Level of education (%) of Group C: n \u00bc 40: 50/50: 44.7\u00b11.4: 34.7\u00b11.8: 44.9\u00b12.8: 2.6\u00b10.6: 34.5\u00b13.1 has a value of 7.7.", "labels": [], "entities": []}, {"text": "The Level of education (%): 50 of Group D: n \u00bc 36: 52.8/47.2: 44.5\u00b11.5: 34.2\u00b12.5: 44\u00b14.2: 4.9\u00b11.2: 32.2\u00b13.2 has a value of 11.1.", "labels": [], "entities": []}, {"text": "The High-school graduate or less of Group A: n \u00bc 94: 30.5/69.5: 44.65\u00b11.25: 37.8\u00b11.7: 48.4\u00b13.6: 3.3\u00b10.4: 27.2\u00b12 has a value of 25.6.", "labels": [], "entities": []}, {"text": "The High-school graduate or less: 40 of Group C: n \u00bc 40: 50/50: 44.7\u00b11.4: 34.7\u00b11.8: 44.9\u00b12.8: 2.6\u00b10.6: 34.5\u00b13.1 has a value of 35.9.", "labels": [], "entities": []}, {"text": "The High-school graduate or less: 40: 50 of Group D: n \u00bc 36: 52.8/47.2: 44.5\u00b11.5: 34.2\u00b12.5: 44\u00b14.2: 4.9\u00b11.2: 32.2\u00b13.2 has a value of 27.8.", "labels": [], "entities": []}, {"text": "The Some education after high-school of Group A: n \u00bc 94: 30.5/69.5: 44.65\u00b11.25: 37.8\u00b11.7: 48.4\u00b13.6: 3.3\u00b10.4: 27.2\u00b12 has a value of 69.5.", "labels": [], "entities": []}, {"text": "The Some education after high-school of Group B: n \u00bc 35: 34.3/65.7: 45.3\u00b11.5: 38.1\u00b12.38: 49.4\u00b14.8: 9.1\u00b13.6*: 35.3\u00b12.8 has a value of 57.1.", "labels": [], "entities": []}, {"text": "The Some education after high-school of Group C: n \u00bc 40: 50/50: 44.7\u00b11.4: 34.7\u00b11.8: 44.9\u00b12.8: 2.6\u00b10.6: 34.5\u00b13.1 has a value of 56.4.", "labels": [], "entities": []}, {"text": "The Some education after high-school: 50 of Group D: n \u00bc 36: 52.8/47.2: 44.5\u00b11.5: 34.2\u00b12.5: 44\u00b14.2: 4.9\u00b11.2: 32.2\u00b13.2 has a value of 61.1.", "labels": [], "entities": []}, {"text": "The NSGT; Group C: bupropion SR and CBGT; Group D: CBGT.", "labels": [], "entities": []}, {"text": "*p < of Group B: n \u00bc 35: 34.3/65.7: 45.3\u00b11.5: 38.1\u00b12.38: 49.4\u00b14.8: 9.1\u00b13.6*: 35.3\u00b12.8: 8\u00b10.3: 14.8\u00b11.2 has a value of 0.05, Group B versus Groups A, C and D..", "labels": [], "entities": []}, {"text": "The rates of Bupropion SR has a value of 44.", "labels": [], "entities": []}, {"text": "The abstinence of Bupropion SR has a value of 30.", "labels": [], "entities": []}, {"text": "The abstinence of Bupropion SR has a value of 42.", "labels": [], "entities": []}, {"text": "The (%) of Bupropion SR has a value of 53.", "labels": [], "entities": []}, {"text": "The (%) of  has a value of 63.", "labels": [], "entities": []}, {"text": "The (%) of Bupropion SR has a value of 49.", "labels": [], "entities": []}, {"text": "The rates of Bupropion SR has a value of 44.", "labels": [], "entities": []}, {"text": "The Continuous of Bupropion SR has a value of 28.", "labels": [], "entities": []}, {"text": "The abstinence of Bupropion SR has a value of 34.", "labels": [], "entities": []}, {"text": "The abstinence of Bupropion SR has a value of 41.", "labels": [], "entities": []}, {"text": "The abstinence of Bupropion SR has a value of 41.", "labels": [], "entities": []}, {"text": "The rates of Bupropion SR has a value of 50.", "labels": [], "entities": []}, {"text": "The Continuous of Bupropion SR has a value of 19 *.", "labels": [], "entities": []}, {"text": "The Continuous of Bupropion SR has a value of 22 *.", "labels": [], "entities": []}, {"text": "The Continuous of Bupropion SR has a value of 22 *.", "labels": [], "entities": []}, {"text": "The Continuous of Bupropion SR has a value of 22 *.", "labels": [], "entities": []}, {"text": "The Continuous of Bupropion SR has a value of 10.", "labels": [], "entities": []}, {"text": "The Continuous of Bupropion SR has a value of 20.", "labels": [], "entities": []}, {"text": "The abstinence of Bupropion SR has a value of 30.", "labels": [], "entities": []}, {"text": "The abstinence of Bupropion SR has a value of 40.", "labels": [], "entities": []}, {"text": "The rates of Bupropion SR has a value of 50.", "labels": [], "entities": []}, {"text": "The (%) of Bupropion SR has a value of 60.", "labels": [], "entities": []}, {"text": "The (%) of  has a value of 70.", "labels": [], "entities": []}, {"text": "The in 3, 6 and: End of: 3 months: 6 months of Bupropion SR has a value of 12 months.", "labels": [], "entities": []}, {"text": "The in 3, 6 and of Bupropion SR has a value of 12 months after the completion of smoking.", "labels": [], "entities": []}, {"text": "The therapy; *p < of Bupropion SR has a value of 0.05, group D versus groups A, B and C..", "labels": [], "entities": []}, {"text": "The Bupropion SR, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%) has a value of 53.2.", "labels": [], "entities": []}, {"text": "The Bupropion SR, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%) has a value of 29.6.", "labels": [], "entities": [{"text": "29.6", "start_pos": 108, "end_pos": 112, "type": "Outcome_value", "confidence": 0.6670212745666504}]}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 62.9.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 28.1.", "labels": [], "entities": [{"text": "28.1", "start_pos": 118, "end_pos": 122, "type": "Outcome_value", "confidence": 0.5815595984458923}]}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 1.489.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.929.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months: 0.672\u00973.302: 0.375\u00972.300 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.327.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months: 0.672\u00973.302: 0.375\u00972.300 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.874.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50 of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 34.3.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50 of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.880.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50 of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 1.239.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50: 0.420\u00971.845: 0.532\u00972.886 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.114.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50: 0.420\u00971.845: 0.532\u00972.886 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.619.", "labels": [], "entities": []}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 22.2*.", "labels": [], "entities": [{"text": "22.2", "start_pos": 103, "end_pos": 107, "type": "Outcome_value", "confidence": 0.7292975187301636}]}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 19.4.", "labels": [], "entities": [{"text": "19.4", "start_pos": 103, "end_pos": 107, "type": "Outcome_value", "confidence": 0.7918456196784973}]}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.251.", "labels": [], "entities": []}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.573.", "labels": [], "entities": []}, {"text": "The CBGT, end of therapy 12 months: 0.104\u00970.609: 0.221\u00971.487 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.002*.", "labels": [], "entities": [{"text": "0.002", "start_pos": 122, "end_pos": 127, "type": "Effect_size_p_value", "confidence": 0.4852791428565979}]}, {"text": "The CBGT, end of therapy 12 months: 0.104\u00970.609: 0.221\u00971.487 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.253.", "labels": [], "entities": []}, {"text": "The *p < of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 0.05: statistically significant, Group D vs Groups A, B and C..", "labels": [], "entities": []}, {"text": "The Insomnia of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 14.9.", "labels": [], "entities": [{"text": "14.9", "start_pos": 94, "end_pos": 98, "type": "Outcome_value", "confidence": 0.5522977113723755}]}, {"text": "The Insomnia of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 18.2.", "labels": [], "entities": [{"text": "18.2", "start_pos": 90, "end_pos": 94, "type": "Outcome_value", "confidence": 0.7699918150901794}]}, {"text": "The Insomnia of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 15.8.", "labels": [], "entities": [{"text": "15.8", "start_pos": 86, "end_pos": 90, "type": "Outcome_value", "confidence": 0.6545349955558777}]}, {"text": "The Insomnia: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Dry mouth of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 14.9.", "labels": [], "entities": [{"text": "14.9", "start_pos": 95, "end_pos": 99, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.5995408296585083}]}, {"text": "The Dry mouth of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 17.2.", "labels": [], "entities": [{"text": "17.2", "start_pos": 91, "end_pos": 95, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.42997315526008606}]}, {"text": "The Dry mouth of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 12.9.", "labels": [], "entities": [{"text": "12.9", "start_pos": 87, "end_pos": 91, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.42037472128868103}]}, {"text": "The Dizziness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 7.3.", "labels": [], "entities": [{"text": "7.3", "start_pos": 95, "end_pos": 98, "type": "Outcome_value", "confidence": 0.591854453086853}]}, {"text": "The Dizziness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 6.2.", "labels": [], "entities": [{"text": "6.2", "start_pos": 91, "end_pos": 94, "type": "Outcome_value", "confidence": 0.702509880065918}]}, {"text": "The Dizziness of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 7.8.", "labels": [], "entities": []}, {"text": "The Constipation of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Constipation of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 5.3.", "labels": [], "entities": [{"text": "5.3", "start_pos": 94, "end_pos": 97, "type": "Outcome_value", "confidence": 0.6252259016036987}]}, {"text": "The Constipation of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.5.", "labels": [], "entities": []}, {"text": "The Constipation: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 1.2.", "labels": [], "entities": []}, {"text": "The Headache of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Headache of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 7.4.", "labels": [], "entities": [{"text": "7.4", "start_pos": 90, "end_pos": 93, "type": "Outcome_value", "confidence": 0.7373347878456116}]}, {"text": "The Headache of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.8.", "labels": [], "entities": []}, {"text": "The Headache: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 4.5.", "labels": [], "entities": []}, {"text": "The Anxiety of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 5.6.", "labels": [], "entities": []}, {"text": "The Anxiety of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 3.1.", "labels": [], "entities": []}, {"text": "The Anxiety of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 4.8.", "labels": [], "entities": []}, {"text": "The Anxiety: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 3.7.", "labels": [], "entities": []}, {"text": "The Nausea of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 5.7.", "labels": [], "entities": []}, {"text": "The Nausea of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 4.3.", "labels": [], "entities": [{"text": "4.3", "start_pos": 88, "end_pos": 91, "type": "Outcome_value", "confidence": 0.5504010319709778}]}, {"text": "The Nausea of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.0.", "labels": [], "entities": []}, {"text": "The Concentration of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 7.3.", "labels": [], "entities": []}, {"text": "The Concentration of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 4.8.", "labels": [], "entities": []}, {"text": "The Concentration of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 4.2.", "labels": [], "entities": []}, {"text": "The Concentration: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 1.2.", "labels": [], "entities": []}, {"text": "The Allergic reaction of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 6.4.", "labels": [], "entities": []}, {"text": "The Allergic reaction of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 3.6.", "labels": [], "entities": []}, {"text": "The Allergic reaction of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.8.", "labels": [], "entities": []}, {"text": "The Sadness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 2.8.", "labels": [], "entities": []}, {"text": "The Sadness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 3.1.", "labels": [], "entities": []}, {"text": "The Sadness of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 2.6.", "labels": [], "entities": []}, {"text": "The Sadness: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 0.4.", "labels": [], "entities": []}, {"text": "The Sleepiness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 1.6.", "labels": [], "entities": []}, {"text": "The Sleepiness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 2.1.", "labels": [], "entities": []}, {"text": "The Sleepiness of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 1.4.", "labels": [], "entities": []}, {"text": "The Hunger of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 1.4.", "labels": [], "entities": []}, {"text": "The Hypertension of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence%: \u0097 has a value of 0.6.", "labels": [], "entities": []}, {"text": "The Hypertension of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B: \u0097 has a value of 0.9.", "labels": [], "entities": []}, {"text": "The Tachycardia of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence%: \u0097: \u0097 has a value of 0.7.", "labels": [], "entities": []}, {"text": "The Tachycardia: \u0097 of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C: \u0097: \u0097 has a value of 0.9.", "labels": [], "entities": []}, {"text": "The Epileptic seizures: \u0097 of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B: \u0097: \u0097 has a value of 0.2.", "labels": [], "entities": []}, {"text": "The Bupropion SR, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%) has a value of 53.2.", "labels": [], "entities": []}, {"text": "The Bupropion SR, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%) has a value of 29.6.", "labels": [], "entities": [{"text": "29.6", "start_pos": 108, "end_pos": 112, "type": "Outcome_value", "confidence": 0.6670212745666504}]}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 62.9.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 28.1.", "labels": [], "entities": [{"text": "28.1", "start_pos": 118, "end_pos": 122, "type": "Outcome_value", "confidence": 0.5815595984458923}]}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 1.489.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.929.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months: 0.672\u00973.302: 0.375\u00972.300 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.327.", "labels": [], "entities": []}, {"text": "The Bupropion SR + NSGT, end of therapy 12 months: 0.672\u00973.302: 0.375\u00972.300 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.874.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50 of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 34.3.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50 of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.880.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50 of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 1.239.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50: 0.420\u00971.845: 0.532\u00972.886 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.114.", "labels": [], "entities": []}, {"text": "The Bupropion SR + CBGT, end of therapy 12 months: 50: 0.420\u00971.845: 0.532\u00972.886 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.619.", "labels": [], "entities": []}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 22.2*.", "labels": [], "entities": [{"text": "22.2", "start_pos": 103, "end_pos": 107, "type": "Outcome_value", "confidence": 0.7292975187301636}]}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 19.4.", "labels": [], "entities": [{"text": "19.4", "start_pos": 103, "end_pos": 107, "type": "Outcome_value", "confidence": 0.7918456196784973}]}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.251.", "labels": [], "entities": []}, {"text": "The CBGT, end of therapy 12 months of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097 has a value of 0.573.", "labels": [], "entities": []}, {"text": "The CBGT, end of therapy 12 months: 0.104\u00970.609: 0.221\u00971.487 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.002*.", "labels": [], "entities": [{"text": "0.002", "start_pos": 122, "end_pos": 127, "type": "Effect_size_p_value", "confidence": 0.4852791428565979}]}, {"text": "The CBGT, end of therapy 12 months: 0.104\u00970.609: 0.221\u00971.487 of N Rovina, I Nikoloutsou et al.: p value: \u0097 has a value of 0.253.", "labels": [], "entities": []}, {"text": "The *p < of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097 has a value of 0.05: statistically significant, Group D vs Groups A, B and C..", "labels": [], "entities": []}, {"text": "The Insomnia of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 14.9.", "labels": [], "entities": [{"text": "14.9", "start_pos": 94, "end_pos": 98, "type": "Outcome_value", "confidence": 0.5522977113723755}]}, {"text": "The Insomnia of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 18.2.", "labels": [], "entities": [{"text": "18.2", "start_pos": 90, "end_pos": 94, "type": "Outcome_value", "confidence": 0.7699918150901794}]}, {"text": "The Insomnia of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 15.8.", "labels": [], "entities": [{"text": "15.8", "start_pos": 86, "end_pos": 90, "type": "Outcome_value", "confidence": 0.6545349955558777}]}, {"text": "The Insomnia: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Dry mouth of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 14.9.", "labels": [], "entities": [{"text": "14.9", "start_pos": 95, "end_pos": 99, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.5995408296585083}]}, {"text": "The Dry mouth of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 17.2.", "labels": [], "entities": [{"text": "17.2", "start_pos": 91, "end_pos": 95, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.42997315526008606}]}, {"text": "The Dry mouth of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 12.9.", "labels": [], "entities": [{"text": "12.9", "start_pos": 87, "end_pos": 91, "type": "Mean_number_of_times_tobacco_used", "confidence": 0.42037472128868103}]}, {"text": "The Dizziness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 7.3.", "labels": [], "entities": [{"text": "7.3", "start_pos": 95, "end_pos": 98, "type": "Outcome_value", "confidence": 0.591854453086853}]}, {"text": "The Dizziness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 6.2.", "labels": [], "entities": [{"text": "6.2", "start_pos": 91, "end_pos": 94, "type": "Outcome_value", "confidence": 0.702509880065918}]}, {"text": "The Dizziness of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 7.8.", "labels": [], "entities": []}, {"text": "The Constipation of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Constipation of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 5.3.", "labels": [], "entities": [{"text": "5.3", "start_pos": 94, "end_pos": 97, "type": "Outcome_value", "confidence": 0.6252259016036987}]}, {"text": "The Constipation of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.5.", "labels": [], "entities": []}, {"text": "The Constipation: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 1.2.", "labels": [], "entities": []}, {"text": "The Headache of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 3.2.", "labels": [], "entities": []}, {"text": "The Headache of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 7.4.", "labels": [], "entities": [{"text": "7.4", "start_pos": 90, "end_pos": 93, "type": "Outcome_value", "confidence": 0.7373347878456116}]}, {"text": "The Headache of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.8.", "labels": [], "entities": []}, {"text": "The Headache: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 4.5.", "labels": [], "entities": []}, {"text": "The Anxiety of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 5.6.", "labels": [], "entities": []}, {"text": "The Anxiety of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 3.1.", "labels": [], "entities": []}, {"text": "The Anxiety of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 4.8.", "labels": [], "entities": []}, {"text": "The Anxiety: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 3.7.", "labels": [], "entities": []}, {"text": "The Nausea of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 5.7.", "labels": [], "entities": []}, {"text": "The Nausea of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 4.3.", "labels": [], "entities": [{"text": "4.3", "start_pos": 88, "end_pos": 91, "type": "Outcome_value", "confidence": 0.5504010319709778}]}, {"text": "The Nausea of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.0.", "labels": [], "entities": []}, {"text": "The Concentration of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 7.3.", "labels": [], "entities": []}, {"text": "The Concentration of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 4.8.", "labels": [], "entities": []}, {"text": "The Concentration of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 4.2.", "labels": [], "entities": []}, {"text": "The Concentration: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 1.2.", "labels": [], "entities": []}, {"text": "The Allergic reaction of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 6.4.", "labels": [], "entities": []}, {"text": "The Allergic reaction of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 3.6.", "labels": [], "entities": []}, {"text": "The Allergic reaction of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 5.8.", "labels": [], "entities": []}, {"text": "The Sadness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 2.8.", "labels": [], "entities": []}, {"text": "The Sadness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 3.1.", "labels": [], "entities": []}, {"text": "The Sadness of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 2.6.", "labels": [], "entities": []}, {"text": "The Sadness: 0.104\u00970.609 of N Rovina, I Nikoloutsou et al.: 95% CI: \u0097: Group D has a value of 0.4.", "labels": [], "entities": []}, {"text": "The Sleepiness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 1.6.", "labels": [], "entities": []}, {"text": "The Sleepiness of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B has a value of 2.1.", "labels": [], "entities": []}, {"text": "The Sleepiness of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C has a value of 1.4.", "labels": [], "entities": []}, {"text": "The Hunger of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence% has a value of 1.4.", "labels": [], "entities": []}, {"text": "The Hypertension of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence%: \u0097 has a value of 0.6.", "labels": [], "entities": []}, {"text": "The Hypertension of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B: \u0097 has a value of 0.9.", "labels": [], "entities": []}, {"text": "The Tachycardia of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Prevalence%: \u0097: \u0097 has a value of 0.7.", "labels": [], "entities": []}, {"text": "The Tachycardia: \u0097 of N Rovina, I Nikoloutsou et al.: Odds ratio: \u0097: Group C: \u0097: \u0097 has a value of 0.9.", "labels": [], "entities": []}, {"text": "The Epileptic seizures: \u0097 of N Rovina, I Nikoloutsou et al.: Abstinence (%): \u0097: Group B: \u0097: \u0097 has a value of 0.2.", "labels": [], "entities": []}]